Evidence map›Paper›PMID 26209817›Full record

ArticleStem cell research2015

Novel source of human hematopoietic stem cells from peritoneal dialysis effluents.

Jinhui Shen, Junke Zheng, Ramesh Saxena, ChengCheng Zhang, Liping Tang

Registry-linked trialAbstract read
In one paragraph

Article in Stem cell research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07667478 (NON-INVASIVE BRAIN STIMULATION FOR MEMORY LOSS IN EARLY ALZHEIMER'S DISEASE), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07667478 narecruitingnot on this mapstarted 2026, after this paper: background citation

Non-invasive brain stimulation for memory loss in early alzheimer's disease

TypeinterventionalSponsorChi-Ying (Roy) LinRan2026 to 2031Enrolled40ConditionsAlzheimer s Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Mild DementiaArmsrepetitive transcranial magnetic stimulation (rTMS), sham repetitive transcranial magnetic stimulation rTMS
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jinhui ShenDepartment of Bioengineering, University of Texas at Arlington, PO Box 19138, Arlington, TX 76019, United States.
Junke ZhengDepartments of Physiology and Developmental Biology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, United States.
Ramesh SaxenaDivision of Nephrology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390, United States.
ChengCheng ZhangDepartments of Physiology and Developmental Biology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, United States. Electronic address: Alec.Zhang@UTSouthwestern.edu.
Liping TangDepartment of Bioengineering, University of Texas at Arlington, PO Box 19138, Arlington, TX 76019, United States; Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung 807, Taiwan. Electronic address: ltang@uta.edu.

Funding

UT Southwestern O'Brien Kidney Research Core CenterP30DK079328 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI MOE, ORSON W · 2007 to 2021
$16.9M
The role of inhibitory receptors in leukemia developmentR01CA172268 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI ZHANG, CHENGCHENG · 2013 to 2017
$1.6M
Biomaterial-mediated fibrotic responsesR01EB007271 · NIBIB · UNIVERSITY OF TEXAS ARLINGTON · PI TANG, LIPING · 2008 to 2011
$1.4M
BIOCOMPATIBILITY: SURFACE INITIATED BIOCHEMISTRYR01GM074021 · NIGMS · UNIVERSITY OF TEXAS ARLINGTON · PI TANG, LIPING · 2005 to 2007
$844k
NCI NIH HHS CA172268NCI NIH HHS R01 CA172268NIBIB NIH HHS EB007271NIBIB NIH HHS R01 EB007271NIDDK NIH HHS P30 DK079328NIDDK NIH HHS P30DK079328NIGMS NIH HHS R01 GM074021
6 · The paper itself

Abstract

Hematopoietic stem cells (HSCs) hold great promise for the treatment of various diseases and blood disorders. However, limited availability of these cells has hampered their applications in clinical and biological research. Here we have identified a new source of autologous human HSCs in peritoneal dialysis (PD) effluents from patients with end stage renal diseases (ESRDs). Cells isolated from PD effluents contain a Lin-/CD34+/CD38-/CD90+ sub-population and can repopulate NOD/SCID/gamma-/- mice in serial transplantation. Differing from cord blood HSCs, PD-derived HSCs have high tendencies to repopulate peritoneal cavity and spleen with myeloid cells and B lymphocytes. Repopulating HSCs also reside in peritoneal cavities in mice. The isolation of HSCs from peritoneal cavities provides a novel and promising source of autologous and functional HSCs for stem cell research and possible clinical use.

Indexed as

Hematopoietic Stem Cell TransplantationADP-ribosyl Cyclase 1AnimalsAntigens, CD34B-LymphocytesFemaleHematopoietic Stem CellsHumansMaleMiceMice, Inbred C57BLMice, Inbred NODMice, SCIDMice, TransgenicMiddle AgedMyeloid CellsADP-ribosyl Cyclase 1Antigens, CD34Thy-1 AntigensHematopoietic stem cellsPeritoneal dialysis

Identifiers

PMID26209817
PMCPMC4600647

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.